T 1389/13 (YKL-40 monoclonal antibodies/BIO-Y) of 10.07.2018
- European Case Law Identifier
- ECLI:EP:BA:2018:T138913.20180710
- Date of decision
- 10 July 2018
- Case number
- T 1389/13
- Petition for review of
- -
- Application number
- 06706064.0
- IPC class
- C07K 16/18A61K 39/00A61P 35/04C07K 14/47A61P 1/16A61P 37/00A61P 35/00A61P 29/00A61K 39/395A61K 38/10A61K 38/08
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- YKL-40 monoclonal antibodies
- Applicant name
- BIO-Y A/S
Regents of the University of California - Opponent name
- Bayer Pharma Aktiengesellschaft
- Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 104European Patent Convention Art 116(1)European Patent Convention Art 123(3)European Patent Convention Art 83European Patent Convention R 115(2)Rules of procedure of the Boards of Appeal Art 13(1)Rules of procedure of the Boards of Appeal Art 15(1)Rules of procedure of the Boards of Appeal Art 15(3)Rules of procedure of the Boards of Appeal Art 16Rules of procedure of the Boards of Appeal Art 17
- Keywords
- Admissibility of appeal (yes)
Main request, AR1-6 - sufficiency of disclosure (no)
AR7,9 - admission into proceedings (no)
AR8 - extended scope (yes)
Apportionment of costs (no) - Catchword
- -
- Cited cases
- T 2285/09
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.
3. The request for apportionment of costs is rejected.